drugset
drugset / Trial / NCT03676322

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

NCT03676322 ↗

Phase 1 Completed 96 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupDouble-blindOther

Summary

The study will evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamics (PD), and explore the food effect of M5049 in healthy male and female participants.

Timeline

Start
2018-09-20
Primary completion
2019-07-26
Completion
2019-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Enpatoran Small molecule — Oral

Indications

No indication recorded.